FDA 483 - AbbVie Bioresearch Center

An FDA inspection of AbbVie Bioresearch Center in Worcester, MA, identified an issue with microbiology methods. The firm was cited for not adequately conducting these methods, specifically regarding the use of qualified inoculum or previously approved media batches for growth promotion acceptance criteria. This indicates a concern with quality control in their drug substance manufacturing processes.